Hier finden Sie schutzrechtlich gesicherte Innovationen aus den Hochschulen Nordrhein-Westfalens und weiteren Forschungseinrichtungen, selektiert in unterschiedliche Technologiegebiete. Über die Suchfunktion können Sie auch direkt nach Schlagworten und Technologien suchen.
14.11.2008 - Ref.-Nr. 1752
HypoPlant - Production of hypo-allergenic glycoproteins in plantsGlycoproteins (GPs) are of prime interest in medical science.
However, the production of GPs by standard methods is still
complex and expensive. Plants have been suggested as
potential cost-effective and safe GP-production system, but
major differences in the final steps of biosynthetic pathways
in mammals and plants lead to different glycosylation
patterns, provoking an immune response when treating
humans with GPs produced in plants.
State of the art approaches are based either on glycosylation
mutants or overproduction of the desired protein product
(intending to override the cellular glycosylation machinery).
Though the mutants either show impaired yield or loss of
vitality in comparison to wild type, or the proteins do not
terminate in mannose residues, which is essential for the
biological uptake via mannose receptors in patients with
lysosomal storage diseases.
This invention provides a new device to generate GPs with
hypo-allergenic properties in a cost-effective way: In contrast
to current methods, the new technique enables effective
production of heterologous GPs by vital plants without
impairments. The technology is based on a genetic
modification of the N-glycosylation pathway. It is applicable
to Solanaceous and other plants of agronomical interest as
transgenic producers of GPs. The suppression of a specific
enzyme leads to a reduction of cross-reactive carbohydrate
determinants (CCD) in general, leading to GPs that are
supposed to have a better tolerance and uptake by humans.
Ausführliches Angebot als pdfKontakt:
Dr. Silvia Schön-Feltes, Tel.: +49 (0) 208 94 105-46
PROvendis GmbH
Tel.: +49 (0)208/94105 10
kontakt@provendis.info